(Q37105236)

English

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

type 2 diabetes

0 references

metabolic syndrome

1 reference

based on heuristic

inferred from title

cardiovascular disease

1 reference

based on heuristic

inferred from title

Marja-Riitta Taskinen

7

object named as

Marja-Riitta Taskinen

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Russell Scott

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Richard O'Brien

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Greg Fulcher

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Chris Pardy

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Michael D'Emden

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Dana Tse

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Christian Ehnholm

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Anthony Keech

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

4 November 2008

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

32

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

493-498

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Metabolic syndrome--what is the clinical usefulness?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

14 September 2017

Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

14 September 2017

Cardiometabolic risk: a Framingham perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

14 September 2017

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

14 September 2017

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

14 September 2017

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

14 September 2017

The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

14 September 2017

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

14 September 2017

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

14 September 2017

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

27 June 2018

Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

3 September 2018

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

3 September 2018

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

3 September 2018

Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

3 September 2018

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

3 September 2018

Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

3 September 2018

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

3 September 2018

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

3 September 2018

Triglycerides and the Risk of Coronary Heart Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2646035

4 December 2018

PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/18984774

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women

1 reference

https://pubmed.ncbi.nlm.nih.gov/18984774

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/18984774

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2337/DC08-1543

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37105236&oldid=1686740013"